Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
CEBPA encodes the transcription factor C/EBPα and is specifically up‐regulated during granulocytic differentiation. The gene is mutated in approximately 20% of patients with acute myeloid leukemia (AML) FAB type M2 and occurs in the absence of the t(8;21). In much the same way as specific translocations are associated with a particular AML FAB type, the identification of non‐random associations of gene mutation with karyotype or FAB type may be helpful in elucidating the molecular basis of certain forms of leukemia. To confirm these initial findings, 99 patients with AML FAB type M1 or M2 were screened for CEBPA mutations by use of a PCR–single‐strand conformational polymorphism and sequencing approach. Nine CEBPA mutations were identified in eight patients. The mutations were clustered toward the COOH terminal of the protein and occurred exclusively in the intermediate cytogenetic risk group (8/64, 12.5%). Two patients with biallelic mutation, one homozygous for 1137Ins (57 bp) and another with two CEBPA mutations, 1096Ins (27 bp) and 363Ins (GGCC), were observed. There was no evidence for deletion of this region in the other six mutated samples analyzed by fluorescence in situ hybridization with a BAC clone spanning the CEBPA locus. CEBPA mutation status was not demonstrated to be of prognostic importance in this patient group, although this may reflect the selection and size of the AML population studied. In conclusion, mutation of CEBPA is a recurrent finding in AML and appears specific to the intermediate cytogenetic risk group patients. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“C/EBP can act synergistically with other proteins important in myeloid development, including RUNX1 (AML1/CBFA2) (Zhang et al., 1996), and CEBPA knockout mice are seen to have an early block in myeloid maturation with a phenotype similar to AML M2 (Zhang et al., 1997).”
BackgroundPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901 · cited 7×
“The RUNX1-CBFA2T1 fusion protein, which occurs in 10–15% of cases of AML, causes an eightfold down-regulation of CEBPA expression (Pabst et al., 2001b).”
BackgroundResultInfluentialErickson, P., Gao, J., Chang, K., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J., & Drabkin, H. (1992) · Blood · doi:10.1182/blood.v80.7.1825.1825 · Cited by 631 · cited 1×
“For example, the t(8;21)(q22;q22) chromosomal translocation, which fuses the core-binding factor gene (CBFA2/RUNX1/AML1) on 21q22 with the CBFA2T1 gene on 8q22 to form the chimeric gene RUNX1-CBFA2T1, is associated with a favorable prognosis (Erickson et al., 1992; Nucifora et al., 1993).”
BackgroundAML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G. (2001) · Nature Medicine · doi:10.1038/86515 · Cited by 463 · cited 7×
“The RUNX1-CBFA2T1 fusion protein, which occurs in 10–15% of cases of AML, causes an eightfold down-regulation of CEBPA expression (Pabst et al., 2001b).”
BackgroundResultInfluentialZhang, D.-E., Hetherington, C. J., Meyers, S., Rhoades, K. L., Larson, C. J., Chen, H.-M., Hiebert, S. W., & Tenen, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1231 · Cited by 396 · cited 7×
“The RUNX1-CBFA2T1 fusion protein, which occurs in 10–15% of cases of AML, causes an eightfold down-regulation of CEBPA expression (Pabst et al., 2001b).”
BackgroundInfluentialSmith, L., Hohaus, S., Gonzalez, D., Dziennis, S., & Tenen, D. (1996) · Blood · doi:10.1182/blood.v88.4.1234.bloodjournal8841234 · Cited by 332
Hohaus, S., Petrovick, M. S., Voso, M. T., Sun, Z., Zhang, D.-E., & Tenen, D. G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5830 · Cited by 284 · cited 1×
“C/EBP is important in the regulation of myeloid differentiation, being expressed particularly in early myeloid cells, in addition to regulating a number of granulocyte-specific genes (Hohaus et al., 1995; Oelgeschlager et al., 1996; Smith et al., 1996; Petrovick et al., 1998).”
BackgroundPreudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000) · Blood · doi:10.1182/blood.v96.8.2862 · Cited by 263 · cited 1×
“For example, RUNX1 mutations have been reported in cases of both AML and myelodysplastic syndrome (Osato et al., 1999; Imai et al., 2000; Preudhomme et al., 2000; Snaddon et al., 2002).”
Backgroundc-Myc Is a Critical Target for C/EBPα in Granulopoiesis
Johansen, L. M., Iwama, A., Lodie, T. A., Sasaki, K., Felsher, D. W., Golub, T. R., & Tenen, D. G. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.11.3789-3806.2001 · Cited by 263
C/EBP, c-Myb, and PU.1 Cooperate To Regulate the Neutrophil Elastase Promoter
Oelgeschläger, M., Nuchprayoon, I., Lüscher, B., & Friedman, A. D. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4717 · Cited by 229 · cited 1×
“C/EBP is important in the regulation of myeloid differentiation, being expressed particularly in early myeloid cells, in addition to regulating a number of granulocyte-specific genes (Hohaus et al., 1995; Oelgeschlager et al., 1996; Smith et al., 1996; Petrovick et al., 1998).”
Background
Cited by
Wouters, B. J., Löwenberg, B., Erpelinck-Verschueren, C. A. J., van Putten, W. L. J., Valk, P. J. M., & Delwel, R. (2009) · Blood · doi:10.1182/blood-2008-09-179895 · Cited by 566
Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M. A., Erpelinck, C. A. J., Wouters, B. J., van der Poel-van de Luytgaarde, S. C., Damm, F., Krauter, J., Ganser, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307280 · Cited by 384
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Mutation of CEBPA in Familial Acute Myeloid Leukemia
Smith, M. L., Cavenagh, J. D., Lister, T. A., & Fitzgibbon, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041331 · Cited by 328
Self-citationC/EBPα mutations in acute myeloid leukaemias
Nerlov, C. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1363 · Cited by 280
Green, C. L., Koo, K. K., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2501 · Cited by 273
Raghavan, M., Lillington, D. M., Skoulakis, S., Debernardi, S., Chaplin, T., Foot, N. J., Lister, T. A., & Young, B. D. (2005) · Cancer Research · doi:10.1158/0008-5472.375.65.2 · Cited by 269
Self-citationSchnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C., & Haferlach, T. (2011) · Blood · doi:10.1182/blood-2009-11-255976 · Cited by 265
Rosmarin, A. G., Yang, Z., & Resendes, K. K. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.015 · Cited by 121
Porse, B. T., Bryder, D., Theilgaard-Mönch, K., Hasemann, M. S., Anderson, K., Damgaard, I., Jacobsen, S. E. W., & Nerlov, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050067 · Cited by 117
Role of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
Metadata
- Authors
- Snaddon, J., Smith, M. L., Neat, M., Cambal‐Parrales, M., Dixon‐McIver, A., Arch, R., Amess, J. A., Rohatiner, A. Z., Lister, T. A., & Fitzgibbon, J.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2003-03-11
- Volume
- 37
- Issue
- 1
- Pages
- 72-78
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2005486003
- Cited by
- 110
- References
- 12
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.